Epidemiology

Synexis® sharpens focus on healthcare market, announces key strategic partnership and quality certification

Retrieved on: 
Tuesday, April 19, 2022

LENEXA, Kan., April 19, 2022 /PRNewswire/ -- Synexis® LLC announced two strategic initiatives that highlight the company's focus and future growth in the healthcare market. Synexis has entered a strategic partnership with the Association for Professionals in Infection Control and Epidemiology (APIC), a key professional organization in infection prevention and the healthcare industry. Synexis also recently completed ISO 9001:2015 certification with TÜV Rheinland® of North America. This certification is recognized and adopted within many industries, including healthcare. This effort highlights the company's commitment to consistency of service, quality assurance, customer satisfaction and continuous improvement.

Key Points: 
  • LENEXA, Kan., April 19, 2022 /PRNewswire/ -- Synexis LLC announced two strategic initiatives that highlight the company's focus and future growth in the healthcare market.
  • Synexis has entered a strategic partnership with the Association for Professionals in Infection Control and Epidemiology ( APIC ), a key professional organization in infection prevention and the healthcare industry.
  • "Certification provides an opportunity to expand our business to new sectors, like the healthcare industry, and clients that require this level of quality management," said Schlote.
  • "By earning the ISO 9001:2015 certification, our customers and partners know they will receive high quality products and services when working with Synexis."

Global Alcohol Use Disorder (AUD) Report 2022 - Insights, Epidemiology and Market Forecasts 2019-2032 Featuring Odyssey pharmaceuticals, Merck Sante & MediciNova - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 19, 2022

The "Alcohol Use Disorder (AUD) - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alcohol Use Disorder (AUD) - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
  • This "Alcohol Use Disorder (AUD)- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alcohol Use Disorder (AUD), historical and forecasted epidemiology as well as the Alcohol Use Disorder (AUD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Alcohol Use Disorder (AUD) market report provides current treatment practices, emerging drugs, Alcohol Use Disorder (AUD) market share of the individual therapies, current and forecasted Alcohol Use Disorder (AUD) market Size from 2019 to 2032 segmented by seven major markets.
  • The Alcohol Use Disorder (AUD) epidemiology division provide insights into the historical and current Alcohol Use Disorder (AUD) patient pool and forecasted trend for every seven major countries.

Insights on the Global Skin Burns Market (2019 to 2032) Includes Segmentation of 7 Major Markets - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 19, 2022

This "Skin Burns- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Skin Burns, historical and forecasted epidemiology as well as the Skin Burns market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Points: 
  • This "Skin Burns- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Skin Burns, historical and forecasted epidemiology as well as the Skin Burns market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Skin Burns market report provides current treatment practices, emerging drugs, Skin Burns market share of the individual therapies, and current and forecasted Skin Burns market Size from 2019 to 2032 segmented by seven major markets.
  • The Report also covers current Skin Burns treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
  • The Skin Burns epidemiology division provide insights about historical and current Skin Burns patient pool and forecasted trend for every seven major countries.

In-depth Report on Celiac Disease (CD) - Market Insight, Epidemiology and Market Forecast - 2019 to 2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 19, 2022

The "Celiac Disease (CD) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Celiac Disease (CD) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This "Celiac Disease (CD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Celiac Disease (CD), historical and forecasted epidemiology as well as the Celiac Disease (CD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Celiac Disease (CD) market report provides current treatment practices, emerging drugs, Celiac Disease (CD) market share of the individual therapies, current and forecasted Celiac Disease (CD) market Size from 2019 to 2032 segmented by seven major markets.
  • The Celiac Disease (CD) market report gives a thorough understanding of the Celiac Disease (CD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Aruvant to Participate in Multiple Conferences This Spring

Retrieved on: 
Tuesday, April 19, 2022

MILLBURN, N.J., and BASEL, Switzerland, April 19, 2022 /PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that the company will participate in multiple conferences this Spring.

Key Points: 
  • MILLBURN, N.J., and BASEL, Switzerland, April 19, 2022 /PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that the company will participate in multiple conferences this Spring.
  • Dr. Malik will also present the ARU-1801 data during the IUBMB meeting that will take place in Crete, Greece, May 5 to 9, 2022.
  • Aruvant has an activeresearchprogram with a lead product candidate, ARU-1801, in development for individuals suffering fromSCD.
  • Follow Aruvant on Facebook , Twitter @AruvantSciences , Instagram @Aruvant_Sciences or LinkedIn @AruvantSciences .

TOMI Announces CEO Shareholder Letter Discussing Preliminary First Quarter Results, Growth Strategy and Share Registration

Retrieved on: 
Monday, April 18, 2022

The company ended the first quarter of 2022 with notable improvements when compared to prior periods in 2021.

Key Points: 
  • The company ended the first quarter of 2022 with notable improvements when compared to prior periods in 2021.
  • We were cash flow positive from operations for the first time since the second quarter of 2020 and maintained our working capital position.
  • We expect first quarter sales to grow approximately 11% over what was reported in the first quarter of 2021 and 15% sequentially over the fourth quarter of 2021.
  • A key driver to our longer-term growth is strengthening demand for our Custom Engineered Systems (CES) from both the life science and hospital sectors.

Global Calciphylaxis Market Insight, Epidemiology and Market Forecast to 2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 15, 2022

The "Calciphylaxis - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Calciphylaxis - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
  • This "Calciphylaxis- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Calciphylaxis, historical and forecasted epidemiology as well as the Calciphylaxis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Calciphylaxis market report provides current treatment practices, emerging drugs, Calciphylaxis market share of the individual therapies, current and forecasted Calciphylaxis market Size from 2019 to 2032 segmented by seven major markets.
  • The Report also covers current Calciphylaxis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Global Anemia In Chronic Kidney Disease Market to 2032 - Insight, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 14, 2022

The "Anemia In Chronic Kidney Disease - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anemia In Chronic Kidney Disease - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Anemia In Chronic Kidney Disease, historical and forecasted epidemiology as well as the Anemia In Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • This report provides current treatment practices, emerging drugs, Anemia In Chronic Kidney Disease market share of the individual therapies, current and forecasted Anemia In Chronic Kidney Disease market Size from 2019 to 2032 segmented by seven major markets.
  • What would be the Anemia In Chronic Kidney Disease market growth till 2032, and what will be the resultant market Size in the year 2032?

Media Release - IPAC Canada Applauds Federal Government's Significant Budget Investment in Public Health Surveillance

Retrieved on: 
Wednesday, April 13, 2022

Winnipeg, Manitoba--(Newsfile Corp. - April 13, 2022) - Infection Prevention and Control Canada (IPAC Canada) applauds the federal government on a historic five-year, $436.2 million dollar investment in public health surveillance and risk assessment capacities at the Public Health Agency of Canada (PHAC).

Key Points: 
  • Winnipeg, Manitoba--(Newsfile Corp. - April 13, 2022) - Infection Prevention and Control Canada (IPAC Canada) applauds the federal government on a historic five-year, $436.2 million dollar investment in public health surveillance and risk assessment capacities at the Public Health Agency of Canada (PHAC).
  • IPAC Canada is a multidisciplinary member-based association committed to public wellness and safety by advocating for best practices in infection prevention and control (IPAC) in all settings.
  • For several years, IPAC Canada members have advocated for a strengthened and integrated public health surveillance system.
  • For more information or media inquiries, please contact IPAC Canada Executive Director, Gerry Hansen.

Global Cervical Cancer Market Size and Trends Report 2022: Market Will Expand to $4.8 Billion in 2030 with Seagen and Genmab Expected to Take Market-Leading Position - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 13, 2022

Global cervical cancer market to experience substantial growth during the forecast period.

Key Points: 
  • Global cervical cancer market to experience substantial growth during the forecast period.
  • Surgery is the standard of care for the treatment of early-stage cervical cancer, while chemoradiation is the most common treatment modality for locally advanced disease.
  • What are the current unmet needs in cervical cancer, which pipeline agents are positioned to counter these unmet needs?
  • Considering major patent expiries, launch of new premium priced agents and expected label expansions
    What are the main corporate trends?